Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 3, 2026

New Crypto Pepeto Binance Listing Update Following Shiba Inu Success and Cardano Price Prediction Target

View original at globenewswire.com
New Crypto Pepeto Binance Listing Update Following Shiba Inu Success and Cardano Price Prediction Target Dubai, UAE, April 02, 2026 (GLOBE NEWSWIRE) -- The new crypto Pepeto just appeared on CoinMarketCap with a live token page, a move that historically signals an exchange listing is days away from going public…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • ADA bullish case only reaches $3.25 for the full year, assuming conditions Cardano has consistently failed to produce

    60% confidence

  • A pair of brothers in New York put $8,000 into Shiba Inu before anyone outside crypto circles had heard of it, and six months later that position was worth $9 million

    60% confidence

  • ADA will reach an upside of just $0.57 for 2026 and $1.89 by 2030

    60% confidence

  • ADA will trade between $0.24 and $0.42 through 2026, with algorithm projecting ADA never reclaiming its all-time high, capping highest estimated price at $0.63 as far out as 2047

    60% confidence

Data points we hold from this source

Pepeto · capital raised8.6 USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com
New Crypto Pepeto Binance Listing Update Following Shiba Inu Success and Cardano Price Prediction Target — Source | Via News | ViaNews EU